방광암 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global bladder cancer therapeutics market size is expected to reach USD 19.20 Billion in 2034 from USD 6.29 Billion in 2025, growing at a CAGR of 13.2% during 2026-2034.This market is expanding as the global burden of bladder cancer increases and treatment options continue to evolve. Bladder cancer management traditionally relies on surgery, chemotherapy, radiation, and immunotherapy, while targeted and newer therapeutic approaches are expanding available treatment strategies. Rising awareness, improvements in diagnostic technologies, and increasing screening among high-risk populations are supporting earlier disease identification. Continued research into molecular characteristics and disease progression is enabling the development of more personalized treatments. Pharmaceutical companies are also increasing investment in oncology pipelines to address unmet needs across early-stage and advanced bladder cancer.

One of the major drivers is the growing adoption of immunotherapy and targeted treatments for patients with advanced or recurrent disease. Research into biomarkers is helping clinicians identify patients who may benefit from specific therapies. Combination treatment strategies are also being evaluated to improve treatment responses and extend survival. Increasing incidence among aging populations, along with established risk factors such as tobacco exposure, further contributes to demand for therapeutics. Improvements in healthcare infrastructure and oncology treatment access in emerging economies are expected to provide additional opportunities for pharmaceutical manufacturers.

Future growth is likely to be shaped by advances in precision oncology, antibody-drug conjugates, immunotherapy combinations, and molecularly targeted medicines. Developers are focusing on improving efficacy while reducing treatment-related toxicity and overcoming resistance. Companion diagnostics may become increasingly important as treatment selection becomes more biomarker-driven. The market could also benefit from improved access to advanced cancer therapies in developing regions. Although regulatory requirements and high treatment costs may create challenges, continued innovation and a strong pipeline of novel therapies are expected to support the long-term development of bladder cancer therapeutics.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug

• Pembrolizumab
• Enfortumab Vedotin
• Avelumab
• Nivolumab
• Erdafitinib
• Nadofaragene Firadenovec
• Nogapendekin Alfa Inbakicept
• Others

By Product Type

• Cytotoxic Chemotherapy
• Immune Checkpoint Inhibitors
• Antibody-Drug Conjugates
• FGFR Inhibitors
• Intravesical Immunotherapy
• Gene Therapy/Viral Vector Therapy
• Others

By Disease Stage

• Non-Muscle-Invasive Bladder Cancer
• Muscle-Invasive Bladder Cancer
• Locally Advanced/Unresectable Bladder Cancer
• Metastatic Bladder Cancer
• Others

By Age Group

• Pediatric
• Adults

By Type

• Branded
• Generic

By Therapy

• Targeted Therapy
• Immunotherapy
• Chemotherapy
• Others

By Route of Administration

• Oral
• Parenteral
• Intravesical

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies
• Specialty Pharmacies

COMPANIES PROFILED

• Merck & Co. Inc., Astellas Pharma Inc., Bristol Myers Squibb Company, Pfizer Inc., Johnson & Johnson, Ferring Pharmaceuticals, ImmunityBio Inc., AstraZeneca plc, UroGen Pharma Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, Eli Lilly and Company, Novartis AG, Amgen Inc., Sanofi S.A., GSK plc, BeiGene Ltd., Exelixis Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BLADDER CANCER THERAPEUTICS MARKET: BY DRUG 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug
• 4.2. Pembrolizumab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Enfortumab Vedotin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Avelumab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Nivolumab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Erdafitinib Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Nadofaragene Firadenovec Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Nogapendekin Alfa Inbakicept Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BLADDER CANCER THERAPEUTICS MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product Type
• 5.2. Cytotoxic Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Immune Checkpoint Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Antibody-Drug Conjugates Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. FGFR Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Intravesical Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Gene Therapy/Viral Vector Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BLADDER CANCER THERAPEUTICS MARKET: BY DISEASE STAGE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Disease Stage
• 6.2. Non-Muscle-Invasive Bladder Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Muscle-Invasive Bladder Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Locally Advanced/Unresectable Bladder Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Metastatic Bladder Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BLADDER CANCER THERAPEUTICS MARKET: BY AGE GROUP 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Age Group
• 7.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BLADDER CANCER THERAPEUTICS MARKET: BY TYPE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Type
• 8.2. Branded Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Generic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL BLADDER CANCER THERAPEUTICS MARKET: BY THERAPY 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast Therapy
• 9.2. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL BLADDER CANCER THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 10.1. Market Analysis, Insights and Forecast Route Of Administration
• 10.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.4. Intravesical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 11. GLOBAL BLADDER CANCER THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 11.1. Market Analysis, Insights and Forecast Distribution Channel
• 11.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 11.3. Drug Stores & Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 11.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 11.5. Specialty Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 12. GLOBAL BLADDER CANCER THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

• 12.1. Regional Outlook
• 12.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 12.2.1 By Drug
  • 12.2.2 By Product Type
  • 12.2.3 By Disease Stage
  • 12.2.4 By Age Group
  • 12.2.5 By Type
  • 12.2.6 By Therapy
  • 12.2.7 By Route Of Administration
  • 12.2.8 By Distribution Channel
  • 12.2.9 United States
  • 12.2.10 Canada
  • 12.2.11 Mexico
• 12.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 12.3.1 By Drug
  • 12.3.2 By Product Type
  • 12.3.3 By Disease Stage
  • 12.3.4 By Age Group
  • 12.3.5 By Type
  • 12.3.6 By Therapy
  • 12.3.7 By Route Of Administration
  • 12.3.8 By Distribution Channel
  • 12.3.9 United Kingdom
  • 12.3.10 France
  • 12.3.11 Germany
  • 12.3.12 Italy
  • 12.3.13 Russia
  • 12.3.14 Rest Of Europe
• 12.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 12.4.1 By Drug
  • 12.4.2 By Product Type
  • 12.4.3 By Disease Stage
  • 12.4.4 By Age Group
  • 12.4.5 By Type
  • 12.4.6 By Therapy
  • 12.4.7 By Route Of Administration
  • 12.4.8 By Distribution Channel
  • 12.4.9 India
  • 12.4.10 Japan
  • 12.4.11 South Korea
  • 12.4.12 Australia
  • 12.4.13 South East Asia
  • 12.4.14 Rest Of Asia Pacific
• 12.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 12.5.1 By Drug
  • 12.5.2 By Product Type
  • 12.5.3 By Disease Stage
  • 12.5.4 By Age Group
  • 12.5.5 By Type
  • 12.5.6 By Therapy
  • 12.5.7 By Route Of Administration
  • 12.5.8 By Distribution Channel
  • 12.5.9 Brazil
  • 12.5.10 Argentina
  • 12.5.11 Peru
  • 12.5.12 Chile
  • 12.5.13 Rest of Latin America
• 12.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 12.6.1 By Drug
  • 12.6.2 By Product Type
  • 12.6.3 By Disease Stage
  • 12.6.4 By Age Group
  • 12.6.5 By Type
  • 12.6.6 By Therapy
  • 12.6.7 By Route Of Administration
  • 12.6.8 By Distribution Channel
  • 12.6.9 Saudi Arabia
  • 12.6.10 UAE
  • 12.6.11 Israel
  • 12.6.12 South Africa
  • 12.6.13 Rest of the Middle East And Africa

Chapter 13. COMPETITIVE LANDSCAPE

• 13.1. Recent Developments
• 13.2. Company Categorization
• 13.3. Supply Chain & Channel Partners (based on availability)
• 13.4. Market Share & Positioning Analysis (based on availability)
• 13.5. Vendor Landscape (based on availability)
• 13.6. Strategy Mapping

Chapter 14. COMPANY PROFILES OF GLOBAL BLADDER CANCER THERAPEUTICS INDUSTRY

• 14.1. Top Companies Market Share Analysis
• 14.2. Company Profiles
  • 14.2.1 Merck & Co. Inc
  • 14.2.2 Astellas Pharma Inc
  • 14.2.3 Bristol Myers Squibb Company
  • 14.2.4 Pfizer Inc
  • 14.2.5 Johnson & Johnson
  • 14.2.6 Ferring Pharmaceuticals
  • 14.2.7 ImmunityBio Inc
  • 14.2.8 AstraZeneca Plc
  • 14.2.9 UroGen Pharma Inc
  • 14.2.10 F. Hoffmann-La Roche Ltd
  • 14.2.11 Merck KGaA
  • 14.2.12 Eli Lilly And Company
  • 14.2.13 Novartis AG
  • 14.2.14 Amgen Inc
  • 14.2.15 Sanofi S.A
  • 14.2.16 GSK Plc
  • 14.2.17 BeiGene Ltd
  • 14.2.18 Exelixis Inc